Zacks claims that Biogen has the "best pipeline in Biotech." They note that at a recent "R&D Day" the company showcased 7 programs that were in stage III trials.
They go on to speculate that big pharma companies would love to buy such a great pipeline. They give the stock a $62 price target.
The Fool has also tapped the stock as one of their official Stock Advisor picks.